Glaukos (NYSE:GKOS) Given New $152.00 Price Target at Truist Financial

Glaukos (NYSE:GKOS) had its price objective lifted by Truist Financial from $145.00 to $152.00 in a research report sent to investors on Monday, Benzinga reports. Truist Financial currently has a buy rating on the medical instruments supplier’s stock.

Several other research analysts also recently commented on GKOS. BTIG Research lifted their target price on Glaukos from $131.00 to $139.00 and gave the stock a buy rating in a research note on Wednesday, August 28th. Piper Sandler lifted their price objective on Glaukos from $110.00 to $140.00 and gave the company an overweight rating in a report on Thursday, August 1st. Needham & Company LLC boosted their price target on Glaukos from $131.00 to $137.00 and gave the stock a buy rating in a report on Thursday, August 1st. Wells Fargo & Company boosted their price objective on Glaukos from $120.00 to $135.00 and gave the stock an overweight rating in a research report on Thursday, August 1st. Finally, Morgan Stanley boosted their price objective on Glaukos from $100.00 to $120.00 and gave the stock an equal weight rating in a research report on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $130.45.

Glaukos Stock Up 2.6 %

Shares of Glaukos stock opened at $130.14 on Monday. The business’s 50 day simple moving average is $127.44 and its 200 day simple moving average is $116.23. Glaukos has a 52-week low of $59.22 and a 52-week high of $136.60. The firm has a market cap of $6.55 billion, a PE ratio of -45.19 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). The firm had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company earned ($0.55) earnings per share. On average, analysts predict that Glaukos will post -2.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $13,216,581.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $13,216,581.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares in the company, valued at $3,614,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,250 shares of company stock worth $4,825,873. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its holdings in Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares during the period. Caldwell Sutter Capital Inc. boosted its stake in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after acquiring an additional 1,465 shares during the last quarter. Fifth Third Wealth Advisors LLC bought a new position in Glaukos during the 2nd quarter valued at $187,000. Procyon Advisors LLC bought a new position in Glaukos during the 3rd quarter valued at $210,000. Finally, Brighton Jones LLC bought a new position in shares of Glaukos in the 2nd quarter worth about $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.